<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513808</url>
  </required_header>
  <id_info>
    <org_study_id>VICTORY</org_study_id>
    <nct_id>NCT04513808</nct_id>
  </id_info>
  <brief_title>Total Intravenous Anesthesia and Recurrence Free Survival</brief_title>
  <official_title>Total IntraVenous AnesthesIa and ReCurrence-free Survival AfTer EsOphageal CanceR SurgerY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to compare recurrence-free survival in patients having potentially&#xD;
      curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to&#xD;
      propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will test the primary hypothesis that recurrence-free survival after&#xD;
      esophageal cancer surgery is longer in patients randomized to propofol-based total&#xD;
      intravenous anesthesia than to volatile sevoflurane anesthesia.&#xD;
&#xD;
      The investigators will test the secondary hypotheses that propofol-based total intravenous&#xD;
      anesthesia: 1) speeds discharge from the ICU; 2) speeds discharge from the hospital; and, 3)&#xD;
      improves the quality of recovery, as assessed by QoR-15 on postoperative day 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>4 years</time_frame>
    <description>The investigators will use the randomized groups to descriptively compared on all baseline variables using summary statistics such as mean and standard deviation, median and quartiles or frequency and percent, as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The treatment effect of propofol-based anesthesia versus volatile anesthesia.</measure>
    <time_frame>up to 2 day</time_frame>
    <description>The investigators will use a Cox proportional hazards time to event model to assess the treatment effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Propofol-based total intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol-based total intravenous anesthesia</intervention_name>
    <description>Patients will normally be given dexamethasone 10 mg and ramosetron 0.3-0.6 mg prophylaxis for postoperative nausea and vomiting. Rescue treatment will be provided per clinical routine. Post-operative analgesia will be opioid-based, typically sufentanil and dezocine via patient-controlled pump. Analgesic adjuvants will be used per clinician preference.</description>
    <arm_group_label>Propofol-based total intravenous anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane intravenous anesthesia</intervention_name>
    <description>Patients will normally be given dexamethasone 10 mg and ramosetron 0.3-0.6 mg prophylaxis for postoperative nausea and vomiting. Rescue treatment will be provided per clinical routine. Post-operative analgesia will be opioid-based, typically sufentanil and dezocine via patient-controlled pump. Analgesic adjuvants will be used per clinician preference.</description>
    <arm_group_label>Sevoflurane intravenous anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed&#xD;
             to be Tumor Stage 1-3).&#xD;
&#xD;
          -  Scheduled for potentially curative esophageal cancer surgery.&#xD;
&#xD;
          -  Written informed consent, including willingness to be randomized to intravenous versus&#xD;
             volatile anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous surgery for esophageal cancer (except diagnostic biopsies) Age &lt;18 or &gt;85&#xD;
             years old.&#xD;
&#xD;
          -  ASA Physical Status ≥4.&#xD;
&#xD;
          -  Any contraindication to propofol or sevoflurane.&#xD;
&#xD;
          -  Other cancer not believed by the attending surgeon to be in long-term remission.&#xD;
&#xD;
          -  Systemic disease believed by the attending surgeon to present ≥25% two- year&#xD;
             mortality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuwei Oui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Sessler, MD</last_name>
    <phone>216-444-4900</phone>
    <email>ds@or.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanhai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Yuwei Qui, MD</last_name>
      <email>qqiuyuweixk@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

